Details

Autor(en) / Beteiligte

• Khan, Khadija
• Lustig, Gila
• Bernstein, Mallory
• Archary, Derseree
• Cele, Sandile
• Karim, Farina
• Smith, Muneerah
• Ganga, Yashica
• Jule, Zesuliwe
• Reedoy, Kajal
• Miya, Yoliswa
• Mthabela, Ntombifuthi
• Magula, Nombulelo P
• Lessells, Richard
• de Oliveira, Tulio
• Gosnell, Bernadett I
• Abdool Karim, Salim
• Garrett, Nigel
• Hanekom, Willem
• Bekker, Linda-Gail
• Gray, Glenda
• Blackburn, Jonathan M
• Moosa, Mahomed-Yunus S
• Sigal, Alex

Titel

Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection and Ad26.CoV2.S Vaccination in People Living With Human Immunodeficiency Virus (HIV)

Ist Teil von

• Clinical infectious diseases, 2022-08, Vol.75 (1), p.e857-e864

Ort / Verlag

US: Oxford University Press

Erscheinungsjahr

2022

Link zum Volltext

Quelle

Oxford Journals 2020 Medicine

Beschreibungen/Notizen

• Abstract Background People living with HIV (PLWH) have been reported to have a higher risk of more severe COVID-19 disease and death. We assessed the ability of the Ad26.CoV2.S vaccine to elicit neutralizing activity against the Delta variant in PLWH relative to HIV-negative individuals. We also examined effects of HIV status and suppression on Delta neutralization response in SARS-CoV-2—infected unvaccinated participants. Methods We enrolled participants who were vaccinated through the SISONKE South African clinical trial of the Ad26.CoV2.S vaccine in healthcare workers (HCWs). PLWH in this group had well-controlled HIV infection. We also enrolled unvaccinated participants previously infected with SARS-CoV-2. Neutralization capacity was assessed by a live virus neutralization assay of the Delta variant. Results Most Ad26.CoV2.S vaccinated HCWs were previously infected with SARS-CoV-2. In this group, Delta variant neutralization was 9-fold higher compared with the infected-only group and 26-fold higher relative to the vaccinated-only group. No decrease in Delta variant neutralization was observed in PLWH relative to HIV-negative participants. In contrast, SARS-CoV-2—infected, unvaccinated PLWH showed 7-fold lower neutralization and a higher frequency of nonresponders, with the highest frequency of nonresponders in people with HIV viremia. Vaccinated-only participants showed low neutralization capacity. Conclusions The neutralization response of the Delta variant following Ad26.CoV2.S vaccination in PLWH with well-controlled HIV was not inferior to HIV-negative participants, irrespective of past SARS-CoV-2 infection. In SARS-CoV-2—infected and nonvaccinated participants, HIV infection reduced the neutralization response to SARS-CoV-2, with the strongest reduction in HIV viremic individuals. Ad26.CoV2.S vaccination of people living with well controlled HIV leads to a non-inferior SARS-CoV-2 Delta variant neutralization. In contrast, previously SAR-CoV-2–infected people living with HIV have lower Delta neutralization capacity, which decreases with HIV viremia relative to HIV-negative individuals.